Comparison of $^{99m}$Tc-Labeled Colloid SPECT/CT and Planar Lymphoscintigraphy in Sentinel Lymph Node Detection in Patients with Melanoma: A Meta-Analysis

Natale Quartuccio 1, Ludovico Maria Garau 2, Annachiara Arnone 1, Marco Pappalardo 3,*, Domenico Rubello 4,*, Gaspare Arnone 1,† and Gianpiero Manca 2,†

1 Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, 90128 Palermo, Italy; natale.quartuccio84@hotmail.it (N.Q.); annachiara.arnone93@gmail.com (A.A.); gasarno@interfree.it (G.A.)
2 Regional Center of Nuclear Medicine, Hospital University of Pisa, 56126 Pisa, Italy; ludovico.garau@gmail.com (L.M.G.); giamanca@gmail.com (G.M.)
3 Division of Plastic and Reconstructive Surgery, Department of Surgical, Oncological, and Oral Sciences, University of Palermo, 90127 Palermo, Italy
4 Nuclear Medicine Unit, Santa Maria della Misericordia Hospital, 35100 Rovigo, Italy
* Correspondence: marcopapp@hotmail.com (M.P .); domenico.rubello@libero.it (D.R.)
† co-last authors.

Received: 10 April 2020; Accepted: 27 May 2020; Published: 2 June 2020

Abstract: We compared the detection rate (DR) for sentinel lymph nodes (SLNs), the number of SLNs and the subjects with additional SLNs of single-photon emission computed tomography (SPECT/CT) and planar lymphoscintigraphy (PL) in patients with melanoma. Furthermore, we evaluated the impact of SPECT/CT on surgical plans. Articles containing head-to-head comparisons between SPECT/CT and PL were searched in Pubmed/MEDLINE and Scopus. The literature search was updated until 31 December 2019. DR was calculated on a per-patient-based analysis; the studies were pooled by their odds ratios (ORs) with a random effects model to assess the significance of difference ($p < 0.05$). The number of additional SLNs (calculated as the relative risk) and pooled proportion of patients with additional SLNs were investigated. The pooled ratio of surgical procedures influenced by the SPECT/CT findings was calculated. Seventeen studies with 1438 patients were eligible for the calculation of DR of SPECT/CT and PL. The average DR was 98.28% (95% confidence interval (95% CI): 97.94–99.19%) for the SPECT/CT and 95.53% (95% CI: 92.55–97.77%) for the PL; OR of 2.31 (95% CI: 1.66–4.18, $p < 0.001$) in favor of the SPECT/CT. There was a relative risk of a higher number of SLNs (1.13) for the SPECT/CT and 17.87% of patients with additional SLNs were detected by SPECT/CT. The average impact of SPECT/CT on surgery resulted in 37.43% of cases. This meta-analysis favored SPECT/CT over PL for the identification of SLNs in patients with melanoma due to a higher DR, reproducibility, number of SLNs depicted, proportion of patients with additional SLNs and the impact on the surgical plan. However, PL remains a good option due to the high values of the DR for SLNs.

Keywords: sentinel lymph node; single photon emission/computed tomography; planar lymphoscintigraphy; $^{99m}$Tc-labeled colloids; melanoma; meta-analysis

1. Introduction

The rationale of identifying and removing the sentinel lymph node (SLN), namely the first lymph node in the lymphatic chain draining the primary tumor, relies on the low probability of subsequent metastatic nodes in the case of a lack of cancerous cells in the histological exam performed in the...
SLN [1,2]. Furthermore, the removal of the SLN avoids the side effects of complete lymph node dissection (CLND) [3,4]. The two main cancers for which SLN biopsy (SLNB) is routinely performed are breast cancer and melanoma [5].

SLNB in patients with melanoma is indicated for T1–T4 stage without clinically evident locoregional or distant metastases [6]. The introduction of SLNB has led to the significant improvement of disease control and better patient outcomes [7]. Reported false negative rates in large cohort trials for patients with melanoma undergoing SLNB range, approximately, from 5% to 20% [8–10].

In recent decades, in the efforts of refining the staging, prognosis and treatment of patients with melanoma, liquid biopsy has emerged as an intriguing technique and different methodological approaches have been proposed to detect circulating tumor cells (CTCs), cell-free circulating tumor DNA (ctDNA) or cell-free circulating microRNA (cmiRNA) [11–15]. The detection of CTCs proved to correlate with worse distant metastasis disease-free survival (DFS), reduced recurrence-free survival [14–16] and in patients with breast cancer, even to the SLN status [17,18]. Furthermore, a role in the prediction of prognosis and the evaluation of disease progression has been suggested for ctDNA or cmiRNA [13]. These methods may help the detection of tumor dissemination that may bypass the SLNs. Nevertheless, SLNs may also be seen as an “incubator” for subsequent metastases; therefore, the surgical resection of a metastatic SLN would still help halting the disease progression and prevent distant metastases [11].

Whereas liquid biopsy has not been widely translated to the clinical setting, the radionuclide localization of sentinel lymph nodes (SLNs) in patients with melanoma is a well established procedure [19]. Despite the recent introduction in the clinical setting of a new receptor-specific radiotracer (99mTc-tilmanocept) which binds the CD 206 macrophage receptor, 99mTc-labeled colloids are still the most widely used radiotracers for the identification of SLNs [20]. All 99mTc-labeled colloids encompass particles with variable sizes, ranging from 5 to 5000 nm, and share the mechanism of accumulation mediated by the particle size at the level of the SLN, where the particles are phagocytized by the macrophages [21].

Planar lymphoscintigraphy (PL) is currently a routine, simple and reliable procedure, performed in most nuclear medicine departments for the identification of sentinel lymph nodes (SLNs) and lymphatic disorders [22,23]; it consists in an initial dynamic acquisition, followed by early and delayed static acquisitions, completed by an acquisition from the neck to the groin [24].

In recent decades, the use of single-photon emission computed tomography/computed tomography (SPECT/CT) has gained wider diffusion in nuclear medicine departments and increasing evidence has been collected about its superior performance in the detection of SLNs over PL. Whereas a superior overall SLN detection has been reported for the 99mTc-labeled colloid SPECT/CT compared to the PL in cervical cancer [25] in a recent meta-analysis (pooled overall SLN detection odds ratio (OR) of 2.5 (95% CI, 1.2–5.3) in favor of SPECT/CT), such evidence has not been systematically assessed for patients with melanoma. The introduction of hybrid scanners, carrying out scintigraphic and morphological imaging in a one-shot examination, enabled nuclear medicine physicians to provide surgeons with more accurate information regarding SLNs (e.g., location, number and surrounding anatomical structures) compared to the PL. Several individual reports have documented the detections of additional SLNs by the means of SPECT/CT compared to the PL and a meaningful impact of SPECT/CT on surgery.

The aim of this study was to perform a meta-analysis of the head-to-head comparison of the detection rate (DR) of PL and SPECT/CT with the 99mTc-labeled colloids in patients with melanoma. Furthermore, as a secondary aim, we assessed whether the SPECT/CT was able to depict a significantly higher number of SLNs than PL and the proportion of surgical procedures influenced by SPECT/CT findings.

2. Materials and Methods

The meta-analysis was conducted in accordance with and in adherence to the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [26]. Before starting the
literature search, a protocol was developed defining the research question, the search methods, the inclusion criteria, the quality assessment, the data extraction and the statistical analysis.

2.1. Literature Search

The PubMed/MEDLINE and Scopus databases were navigated by two researchers to retrieve prospective or retrospective single or multicenter studies, carrying out PL and SPECT/CT in patients with melanoma.

For our primary outcome (detection rate), we selected the articles reporting the DR of PL and SPECT/CT for SLNs (at least 1 lymph node) in patients with melanoma. For our secondary outcomes, we selected articles reporting information on (1) the number of SLNs detected by SPECT/CT and PL, (2) the number of patients with additional SLNs detected by SPECT/CT and/or PL, and (3) the percentage of surgical plans changed on the basis of the SPECT/CT findings.

The search strings were designed to capture the concepts of melanoma, SLN, SPECT/CT and PL within the title and the abstracts of articles. No date limit or language restriction was applied. The literature search was updated until December 31st, 2019. All the identified references were exported to a reference management software (Endnote v. X7.5, Clarivate Analytics, Philadelphia, PA, United States).

2.2. Study Selection

An investigator screened the titles and abstracts of the retrieved records. Only original articles were selected. For each outcome of the present meta-analysis, articles from the same authors with a risk of patient overlap were also excluded, selecting only the study with the largest number of patients. Duplicates were identified using Endnote. After excluding duplicates and non-original articles, the full texts of the remaining articles were retrieved to verify the inclusion criteria.

The full texts were checked to verify the following inclusion criteria: (1) a study cohort or a subset of a minimum of 10 patients with melanoma undergoing both SPECT/CT and PL in the same day for the identification of SLNs; (2) the injection of $^{99m}$Tc-nanocolloids; and (3) no evidence of other malignancies. Articles in languages other than English were translated by native speakers and included in the meta-analysis. The references of the retrieved articles were also screened for additional studies.

2.3. Data Extraction

The data of all included studies in the meta-analysis were independently extracted by two researchers and any disagreement was resolved in a consensus meeting. Bibliographical and technical data extracted from the articles included: the authors, publication year, tracer, tracer activity (expressed in Mega-Becquerel, MBq), number of tracer injections and the approximate timing of SPECT/CT post injection (expressed in minutes). The information regarding melanoma encompassed the anatomical site and the Breslow thickness.

For the outcome relative to the impact of SPECT/CT on surgical plans, the percentage of surgical approaches influenced by SPECT/CT was based on the surgeon’s judgement retrieved from the articles. The percentage was calculated taking into account the surgical procedures in which the imaging technique determined the following events: (1) a change in location, the size or accuracy of the incision; (2) the localization of an SLN in an accessible anatomical site to the surgery; (3) the SPECT/CT guided the surgeons to SLNs that were undetected on planar images or to SLNs in another basin.

For each article, the following data of the patient sample were retrieved: the number of subjects, sex, age, body max index (BMI), average DR ($\geq$1 SLN) for both the SPECT/CT and PL, along with the absolute number of patients with at least one SLN depicted by SPECT/CT and/or PL, the total number of SLNs detected by SPECT/CT and PL, the number of patients with additional SLNs detected by SPECT/CT or PL and the proportion of patients with changes in surgical management based on the SPECT/CT findings.
2.4. Methodological Quality Assessment

The methodological quality of the studies was assessed by an investigator using version 2 of the “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2) [27], which comprises four domains: patient selection, index test, reference standard, flow and timing. The concerns about the risk of bias or applicability were described as low, high or unclear.

2.5. Statistical Analysis

Statistical analysis was carried out using the MedCalc Statistical Software version 19.1.3 (MedCalc Software, Ostend, Belgium; https://www.medcalc.org; 2020). Publication bias was assessed by the visual inspection of the funnel plots. The $I^2$ statistic was used to measure the degree of inconsistency across the studies, with $I^2$ values of 25%, 50% and 75% representing low, moderate, and high substantial heterogeneity. The interpretation of heterogeneity was carried out at a significance level of $p = 0.05$. The choice of fixed or random effects model to calculate the meta-analytic estimates was made on the basis of the degree of inconsistency, selecting the random effects model in the case of moderate and high substantial heterogeneity. The DR was defined on the basis of the detection of at least one SLN in a single patient. The overall pooled DR was calculated for the SPECT/CT and the PL on a per patient-based analysis and presented using forest plots. In order to assess any statistically significant difference ($p < 0.05$) between the two pooled DRs of the SPECT/CT and PL, the studies were pooled by their odds ratios (ORs) with an inverse variance-weighted random effects model. The number of SLNs detected by SPECT/CT and PL was compared pooling the ORs with an inverse variance-weighted random effects model. The average proportion of patients with additional SLNs detected by each technique compared to the other one and the impact of the SPECT/CT on the surgery were pooled across the studies and presented in the form of percentages in a per patient analysis.

3. Results

3.1. Literature Search and Eligibility Assessment

The comprehensive computer literature search from the PubMed/MEDLINE and Scopus databases revealed 564 articles (Figure 1). Of these, 220 items were duplicates and excluded. Reviewing titles and abstracts, 307 out of 344 articles were excluded because they were not in the field of interest of this meta-analysis or because they were non-original articles. The full text of the remaining 37 studies was evaluated for the inclusion in the meta-analysis. After checking the full-text, 19 articles were excluded. One additional record was retrieved after cross checking the references. The characteristics of the 20 studies [28–47] selected for the meta-analysis were presented in Table 1. Only 17/19 studies with a total number of 1438 patients were available for the calculation of the pooled DR of the SPECT/CT and PL. Another 14/20 studies were eligible for the calculation of the proportion of patients with additional SLNs in one of the two techniques. Additionally, 15/20 studies were used to compare the number of SLNs detected by the two techniques. Then, 13/20 studies were eligible for the assessment of the average percentage of patients in whom SPECT/CT may have influenced the surgical management. A summary of the data extracted from the studies is available in Table 2.

The risk of bias for the 17 studies included in the meta-analysis to calculate the pooled DR (primary outcome) was scored as low by using the QUADAS-2. No publication bias was detected (Figure 2).
Figure 1. Flow diagram of the literature search. SPECT/CT, single-photon emission computed tomography; PL, planar lymphoscintigraphy; SLNs, sentinel lymph nodes.

Figure 2. Version 2 of the “Quality Assessment of Diagnostic Accuracy Studies” tool (QUADAS-2) results.
### Table 1. Characteristics of the twenty studies selected for the meta-analysis.

| Authors          | Year | Country         | Tracer                          | Tracer Activity (MBq) | Tracer Injections | Time Interval (Tracer Injection–SPECT/CT) in min | Anatomical Region | BMI (Mean ± SD) | Breslow Thickness in mm | Number of Patients | M   | F   | Age (Mean ± SD/Median; Range) in Years |
|------------------|------|-----------------|---------------------------------|-----------------------|-------------------|-----------------------------------------------|-------------------|----------------|----------------------------|------------------|-----|-----|-------------------------------------|
| Benke            | 2018 | Poland          | 99mTc-Nanocoll                  | 5–20                  | 2–6               | 60–180                                        | Trunk             | NR             | median: 2.0 ± 3.13             | 255              | 160 | 95  | median: 61 (17–88)                |
| Bennie           | 2015 | South Africa    | 99mTc-Nanocoll, 99mTc-Sentiscint | NR                    | 4                 | 60                                           | Trunk, upper limb, lower limb | 28.5 (n = 23) | NR             | 42                          | 22               | 20  |     | mean: M: 50. F:52                 |
| Borbón-Arce      | 2014 | Spain           | 99mTc-Nanocoll                  | Median: 85 (66–158)    | 3–4               | 120                                          | Head and neck     | NR             | mean: 2.7 (1.0–6.0); median: 2.0 | 16               | 9   | 7   | mean: 58 (41–77)                 |
| Brouwer          | 2012 | The Netherlands | ICG–99mTc-nanocolloid           | 70                    | 4                 | 120                                          | Head and neck     | NR             |              | 11               | 5   | 6   | mean: 54 (32–75)                 |
| Even-Sapir       | 2003 | Israel          | 99mTc-rhenium colloid           | 74                    | 4                 | NR                                           | Trunk, head and neck, upper limb, lower limb, penis | NR             | NR             | 15 *                        | 12               | 3   |     | mean: 57.6 (24–81)               |
| Fairbairn        | 2013 | Scotland        | 99mTc-Nanocoll                  | 20 or 40              | 2 or 4            | 60                                           | Trunk, head and neck, upper limb, lower limb | NR             | NR             | 32                          | 12               | 20  |     | 55 ± 13.66 (17–77)              |
| Jimenez-Helfernan| 2015 | Spain           | 99mTc-Nanocoll                  | Mean: 30 ± 27.4       | 1–6               | NR                                           | All regions       | NR             | 0.75–4                     | 262              | 117 | 145 | 53.9 ± 15.2                      |
| Klode #          | 2011 | Germany         | 99mTc-Nanocoll                  | 16 or 80              | 4                 | 120                                          | Head and neck     | NR             | 2.26 (1–7.5); median: 1.7   | 34               | NR  | NR  | NR                                  |
| Kraft #          | 2012 | Czech Republic  | 99mTc-Nanocs, 99mTc-Nanocoll, 99mTc-SentiScint, 99mTc-Nano Albumon | 100                  | 4                 | NR                                           | Trunk, head and neck, upper limb, lower limb | 29.4 ± 12.5     | NR             | 113                         | 59               | 54  |     | mean: 57.6 (11–87)               |
| Kraft            | 2012 | Czech Republic  | 99mTc-Nanocs, 99mTc-Nanocoll, 99mTc-SentiScint, 99mTc-Nano Albumon.      | 100                  | 4                 | NR                                           | All regions       | 28.4 ± 5.1     | NR             | 161                         | 87               | 74  |     | 57.1 ± 14.8                      |
| Lopez-Rodriguez  | 2016 | Spain           | 99mTc-Nanocoll                  | 74                    | At least 4        | NR                                           | Head and neck     | NR             | mean: 2.96 (1–6)          | 22               | 13  | 9   | mean: 55 (24–83)                 |
| Martinez Castillo| 2014 | Spain           | 99mTc-Nanocoll                  | 74                    | 4                 | NR                                           | Trunk, head and neck, upper limb, lower limb | NR             | NR             | 63                          | 32               | 31  |     | 55 (25–88)                       |
Table 1. Cont.

| Authors          | Year | Country    | Tracer                          | Tracer Activity (MBq) | Tracer Injections | Time Interval (Tracer Injection–SPECT/CT) in min | Anatomical Region                          | BMI (Mean ± SD) | Breslow Thickness in mm | Number of Patients | M  | F  | Age (Mean ± SD/Median; Range) in Years |
|------------------|------|------------|--------------------------------|-----------------------|-------------------|-----------------------------------------------|-------------------------------------------|----------------|------------------------|-------------------|----|----|--------------------------------------|
| Mucientes Rasilla| 2009 | Spain      | 99mTc-nanocolloids (not specified) | 74                    | 4                 | NR                                           | Trunk, head and neck, upper limb, lower limb | NR            | mean: 1.75 ± 1.15 (0.47–4.45) | 18                | 8  | 10 | 57.1 ± 20.1 (14–83)          |
| Nielsen          | 2011 | Denmark    | 99mTc-antimony sulphide colloid | 40–80                 | 1–2               | NR                                           | Trunk, head and neck, upper limb, lower limb | NR            | 1–4                    | 307               | 177 | 130 | 60 ± 16.9                 |
| Tew              | 2017 | Australia  | 99mTc-antimony sulphide colloid | 8 or 26 MBq per injection up to 4 | NR | NR                                           | Trunk, head and neck, upper limb, lower limb | NR            | NR                     | 86                | 53 | 33  | mean: 58.8 (22–84)         |
| Trinh #          | 2018 | USA        | 99mTc-filtered sulphur colloid  | Mean: 37 ± 10%        | NR                | NR                                           | Head and neck                                | NR            | NR                     | 118               | 87 | 31  | 58.9 ± 16.7; median: 61 (16–91) |
| van der Ploeg    | 2009 | The Netherlands | 99mTc-Nanocoll | 80                    | 4                 | 120                                          | Trunk, head and neck, upper limb, lower limb | NR            | NR                     | 85                | NR | NR  | mean: 54                  |
| Veenstra         | 2012 | The Netherlands | 99mTc-Nanocoll | 69.8 (mean)           | NR                | 120                                          | Trunk, head and neck, upper limb, lower limb | NR            | at least 1; or less if Clark level = 4 | 35                | 14 | 21  | mean: 60                  |
| Vermeeren        | 2011 | The Netherlands | 99mTc-Nanocoll | 71 (mean)            | 4                 | 120                                          | Head and neck                                | NR            | mean: 2.9 (0.8–7.8); median: 2.2 | 38                | 30 | 8   | mean: 53 (24–86)           |
| Zender           | 2014 | USA        | 99mTc-microfiltered sulfur colloid | 18–37                 | NR                | NR                                           | Head and neck                                | NR            | mean: 2.68 (1.13–7.0)      | 14                | 9  | 5   | mean: 65.43 (31–89)        |

MBq = Mega-Becquerel; BMI = body mass index; SD = standard deviation; M = male; F = female; NR = not reported; ICG = indocyanine green; # not included in the analysis of primary outcome of the meta-analysis (values of DR not available; DR = detection rate). *extracted from a mixed study population of patients with malignant melanoma and patients with squamous cell carcinoma.
Table 2. The data extracted from the twenty studies selected for the meta-analysis.

| Authors                | Number of Patients | DR of SPECT/CT (%) | DR of PL (%) | Number of SLNs Detected by SPECT/CT | Number of SLNs Detected by PL | % of Patients with Additional SLNs in SPECT/CT | % of Patients with Change in Surgical Plan Based on SPECT/CT | Findings |
|------------------------|--------------------|--------------------|--------------|-------------------------------------|-----------------------------|---------------------------------------------|-----------------------------------------------------|----------|
| Benke                  | 255                | 99.21              | 92.54        | 497                                 | 419                         | 15.69                                       | NR                                                  |          |
| Bennie                 | 42                 | 100                | 90.48        | NR                                  | NR                          | 9.52                                        | 40.48                                              |          |
| Borbón-Arce            | 16                 | 100                | 100          | 66                                  | 55                          | NR                                          | NR                                                  |          |
| Brouwer                | 11                 | 100                | 100          | 27                                  | 27                          | 0.00                                        | NR                                                  |          |
| Even-Sapir             | 15 *               | 100                | 93.33        | NR                                  | NR                          | NR                                          | 35.71                                              |          |
| Fairbairn              | 32                 | 96.88              | 96.88        | 67                                  | 65                          | 18.75                                       | 37.50                                              |          |
| Jimenez-Heffernan      | 262                | 99.24              | 98.85        | 602                                 | 532                         | 20.20                                       | 37                                                  |          |
| Klode                  | 34 *               | NR                 | NR           | NR                                  | NR                          | NR                                          | 26.47                                              |          |
| Kraft                  | 113                | NA                 | NA           | NA                                  | NA                          | 43.36                                       | NR                                                  |          |
| Kraft                  | 161                | 92.50              | 85.70        | 487                                 | 351                         | NR                                          | NR                                                  |          |
| Lopez-Rodriguez        | 22                 | 95.45              | 90.90        | NR                                  | NR                          | 27.27                                       | 63.63                                              |          |
| Martinez Castillo      | 63                 | 100                | 98.41        | 266                                 | 222                         | 42.86                                       | 21.20                                              |          |
| Mucientes Rasilla      | 18                 | 100                | 88.88        | 31                                  | 27                          | 16.67                                       | 22.22                                              |          |
| Nielsen                | 307                | 100                | 99.67        | 709 **                              | 692 **                      | NR                                          | NR                                                  |          |
| Tew                    | 86                 | 94.20              | 95.35        | 143                                 | 144                         | 0.00                                        | 39.00                                              |          |
| Trinh                  | 118                | NR                 | NR           | 268                                 | 234                         | NR                                          | NR                                                  |          |
| van der Ploeg          | 85                 | 100                | 98.82        | 226                                 | 214                         | 8.24                                        | 35.29                                              |          |
| Veenstra               | 35                 | 100                | 100          | 77                                  | 69                          | 20.00                                       | 31.42                                              |          |
| Vermeeren              | 38                 | 100                | 100          | 94                                  | 94                          | 15.79                                       | 55.00                                              |          |
| Zender                 | 14                 | 92.86              | 85.71        | 21                                  | 17                          | 28.57                                       | 57.00                                              |          |

DR = detection rate; NA = not applicable; * Extracted as a subset of patients; ** calculated as: mean SLN/patient x number of patients; *** calculated in a subset of 20 patients.
3.2. Detection Rate

In a per-patient analysis, the overall average DR for the SLNs of SPECT/CT was 98.28% (95% confidence interval (95% CI): 97.94–99.19%), and 95.53% (95% CI: 92.55–97.77%) for PL (Figures 3 and 4). The DR rate of the SPECT/CT for SLNs ranged from 92.5% to 100% across the studies. The DR rate of PL for SLNs ranged from 85.71% to 100%. The consistency of the detection appeared highly heterogeneous for the PL ($I^2 = 78.96\%$), whereas the heterogeneity was moderate for the SPECT/CT ($I^2 = 62.45\%$). The significant difference of DR was found: the pooled SLN detection OR of 2.31 (95% CI: 1.66–4.18, $p < 0.001$) in favor of the SPECT/CT. The consistency of a higher DR of SPECT/CT compared to the PL for SLN was found across the study ($I^2 = 0\%$, CI 95%: 0–39.95%).

In a per-patient analysis, taking into account only the studies focusing on subjects with a head and neck melanoma (five studies, 101 patients), the pooled DR of the SPECT/CT for SLNs was 97.27% (95% CI: 93.33–99.50%), whereas the DR of the PL was 95.59 (95% CI: 88.58–99.39%). No significant difference of DR was found between the SPECT/CT and PL with an OR of 2.13 in favor of SPECT/CT (95% CI: 0.36–12.50, $p = 0.4$).
3.3. Comparison of Number of SLNs Detected by SPECT/CT and PL

Fifteen articles enrolling 1614 patients reported the number of SLNs detected by SPECT/CT and PL. SPECT/CT depicted a higher number (3587 vs. 3162) of SLNs compared to PL, favoring the use of SPECT/CT with a statistically significant OR of 1.14 (95% CI: 1.06–1.2; \( p < 0.001 \), random effects model) and a substantial high heterogeneity (\( I^2 = 97.17\% \)). In only one article, PL depicted more SLNs than SPECT/CT (144 vs. 143). In the sub-analysis of the studies (n = 5) reporting data on head and neck melanoma (197 patients), there was a statistically significant difference between the number of SLNs detected by the two techniques (427 vs. 487) with an OR of 1.13 in favor of the SPECT/CT (95% CI: 1.06–1.2; \( p < 0.001 \), random effects model) and moderate heterogeneity (\( I^2 = 60.08\% \)).

3.4. Average Proportion of Patients with Additional SLNs Detected by SPECT/CT or PL

The assessment of the proportion of patients with additional SLNs depicted by each technique could be extracted from 14 articles. Taking into account a total sample size of 1076, the pooled average proportion of patients in whom SPECT/CT depicted additional SLNs was 17.87% (95% CI: 10.9–26.12%). The inconsistency among articles was high (89.56%); the proportion of patients with additional SLNs depicted by SPECT/CT ranged from 0 (two studies including 11 and 86 patients) to 43.36% (in a study with 113 patients). In one article, PL depicted an additional SLN in one patient that could not be detected by SPECT/CT. In patients with head and neck melanoma (four articles for a total of 85 patients), the pooled percentage of subjects with additional SLNs identified using SPECT/CT was 18.10% (95% CI: 10.9–26.12).

3.5. Impact on Surgery of SPECT/CT

The pooled percentage of cases influenced by the use of SPECT/CT (13 studies enrolling 742 patients) was 37.43% (95% CI: 31.95–43.08%). The corresponding percentage of the patients in the studies focusing on head and neck melanoma (four studies including 104 patients) was 49.38% (95% CI: 32.28–66.56%).
4. Discussion

In this meta-analysis, we focused on articles comparing SPECT/CT and PL in the same patients rather also including studies with parallel data collection of SPECT/CT and PL in two different patient groups. We believe that this approach allows a more robust investigation of the research question because the patients may serve as their own control.

A very high rate of successful SLNs was detected using PL in institutions with adequate experience [48]. However, the introduction of SPECT/CT in protocols for the identification of SLNs in patients with melanoma has been advocated due to the increasing scientific evidence for a number of its additional advantages over planar imaging [24]. Firstly, SPECT/CT demonstrates a higher DR than PL. In a meta-analysis collecting articles with paired and parallel data in patients with head and neck melanoma undergoing SPECT/CT (n = 207) and lymphoscintigraphy (n = 208), the pooled median DR was 98.6% for SPECT/CT (range: 92.2–100.0%) and 85.3% for the lymphoscintigraphy (range, 70.0–100.0%) [25]. Whereas, in our meta-analysis, the higher DR of the SPECT/CT compared to the PL was demonstrated in the collection of studies including patients with melanoma located in all regions, the finding was not confirmed when performing a sub-analysis limited to patients with head and neck melanoma (DR: SPECT/CT = 97.27%, PL = 95.59%; OR of 2.13 in favor of SPECT/CT, p = 0.4). It is possible to postulate that this discrepancy may depend on the small patient sample derived from the aggregated studies (n = 101 patients, five studies). Despite the marginally larger DR in SPECT/CT, we advocate the use of SPECT/CT in patients with melanoma because a higher DR is correlated to a lower false negative rate and improved DFS. Likewise, the number of detected SLNs per patient has also been demonstrated to be a significant positive prognostic factor for DFS [49].

Further advantages of SPECT/CT over PL include the higher spatial resolution, the precise anatomical localization of the SLN, also defining the relationship to critical anatomical structures [50] and the efficient attenuation correction through exploiting the CT data [25,51].

From our meta-analysis, it can be derived that the results obtained using the SPECT/CT may present higher repeatability than PL, as highlighted by the lower heterogeneity index ($I^2$) obtained for the SPECT/CT ($I^2 = 62.45\%$ vs. 78.96%). Another meta-analysis, taking into account patients with papillary thyroid cancer undergoing SLNB, revealed an overall DR of 93% (95% CI: 86–97%) for SPECT and 96% (95% CI: 90–98%) for lymphoscintigraphy; however, while there was a moderate inconsistency for the lymphoscintigraphy data ($I^2 = 68\%$), there was no heterogeneity for SPECT/CT ($I^2 = 0\%$) [52].

Our analyses documented a larger number of SLNs detected by SPECT/CT compared to PL (OR: 1.14 in favor). However, these data seem more consistent for patients with head and neck melanoma ($I^2 = 60.08\%$) across the studies. A higher DR and the larger number of SLNs identified by the SPECT/CT on a head-to-head comparison with PL can theoretically also determine a meaningful impact in surgical decision making. Nevertheless, the preoperative use of SPECT/CT for the identification of SLNs is not only important for the additional number of SLNs but also for the capability of providing anatomical information [21,53]. Furthermore, SPECT/CT may also localize unspecific hot spots that could be mistaken as additional SLNs using only PL [54].

SPECT/CT seems to provide a meaningful impact on surgery, possibly influencing the patient outcome [55]. The large prospective multicenter International Atomic Energy Agency Sentinel Node Trial demonstrated that SPECT/CT had modified the surgical approach in 97 patients with melanoma (37% of the patient population): 41.6%, 39.7%, 33.3% and 30.2% of subjects with head and neck, trunk, lower limb and upper limb lesions, respectively [34]. We found a 37.43% change rate in surgical approaches in patients with melanoma located in all regions and changes in 49.38% of cases for patients with head and neck melanoma. These data, taken together, suggest that factors beyond the additional number of detected SLNs contribute to the change in the surgical plan. A more precise localization of SLNs may lead to a more precise surgical procedure (due to a change in the location, size and accuracy of the incision), facilitating the surgical planning, reducing the morbidity, the duration of surgical operations and the costs [55]. In this regard, Stofels et al. performed a cost-effectiveness comparative studies between PL alone (254 patients) and PL + SPECT/CT (149 patients) resulting in a mean cost
saving when using the second option (€ 710.50), mainly due to a reduction in operative time, shortened hospital stay duration and the more frequent use of local anesthesia [55].

Some limitations should be taken into account in our meta-analysis. The selected studies provided variable sample sizes (ranging from 11 to 307 patients). We cannot be sure whether the DR in studies with a smaller number of patients could be influenced by a lower experience in the identification of SLNs. Another source of bias may derive from the moderate and substantial high heterogeneity we found during the assessment of the studies for the primary and secondary outcomes of the present meta-analysis. Further sources of bias may arise from some methodological differences across the studies including the number of radiotracer injections, total injected activity and the time interval between tracer injection, PL and the execution of SPECT/CT.

5. Conclusions

The present meta-analysis provides data that favors the use of SPECT/CT with 99mTc-labeled colloids over PL for the identification of SLNs in patients with melanoma due to the higher DR and reproducibility of the results. However, in institutions where SPECT/CT is not available, PL remains a good option due to its high values of DR for SLNs. SPECT/CT is able to detect additional SLNs compared to PL and may influence surgery in a high percentage of cases. Its impact on surgery may be particularly meaningful in patients with head and neck melanoma.

Although SPECT/CT allows a better surgical planning, there are still cases in which SPECT/CT still does not facilitate the surgical approach and the surgeons do not find an accurate correspondence between the skin marker and the anatomical location of the SLN. In this sense, the widespread of portable gamma-cameras and freehand SPECT may be helpful [56]. Furthermore, future studies with SPECT/CT for the identification of the SLN may focus on the comparison between radiolabeled colloids with fluorescence/hybrid tracers.

Author Contributions: N.Q. designed the study, performed the literature search and statistical analysis; L.M.G. contributed to the statistical analysis and revision of the manuscript; A.A. contributed to the literature search and the initial draft of the paper; G.A. contributed to the conception and revision of the manuscript; M.P. carried out the final revision of the manuscript; D.R. and G.M. edited the manuscript and gave the final approval for the submission. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Moncayo, V . M.; Aarsvold, J . N.; Alazraki, N . P. Lymphoscintigraphy and sentinel nodes. J. Nucl. Med. 2015, 56, 901–907. [CrossRef]
2. Arnone, G. Ruolo Clinico Dell’imaging Integrato nel Melanoma; Mattioli 1885: Fidenza, Italy, 1998.
3. Sim, F. H.; Taylor, W. F.; Ivins, J. C.; Pritchard, D. J.; Soule, E. H. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 1978, 41, 948–956. [CrossRef]
4. Manca, G.; Romanini, A.; Pellegrino, D.; Borso, E.; Rondini, M.; Orlandini, C.; Zucchi, V.; Pasqualetti, F.; Mariani, G. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma. J. Nucl. Med. 2008, 49, 1769–1775. [CrossRef] [PubMed]
5. Gangi, A.; Essner, R.; Giuliano, A. E. Long-term clinical impact of sentinel lymph node biopsy in breast cancer and cutaneous melanoma. Q. J. Nucl. Med. Mol. Imaging 2014, 58, 95–104. [PubMed]
6. Wong, S. L.; Faries, M. B.; Kennedy, E. B.; Agarwala, S. S.; Akhurst, T. J.; Ariyan, C.; Balch, C. M.; Berman, B. S.; Cochran, A.; Delman, K. A.; et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update. J. Clin. Oncol. 2018, 36, 399–413. [CrossRef]
7. Manca, G.; Rubello, D.; Romanini, A.; Mariani, G. False-negative sentinel lymph node biopsy in melanoma patients. Nucl. Med. Commun. 2014, 35, 989–994. [CrossRef]
8. Testori, A.; De Salvo, G.L.; Montesco, M.C.; Trifiro, G.; Mocellin, S.; Landi, G.; Macripo, G.; Carcoforo, P.; Ricotti, G.; Giudice, G.; et al. Clinical considerations on sentinel node biopsy in melanoma from an italian multicentric study on 1313 patients (solism-imi). *Ann. Surg. Oncol*. 2009, 16, 2018–2027. [CrossRef]
9. Nowecki, Z.I.; Rutkowski, P.; Nasierowska-Guttmejer, A.; Ruka, W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. *Ann. Surg. Oncol*. 2006, 13, 1655–1663. [CrossRef]
10. Cascinelli, N.; Bombardieri, E.; Bufalino, R.; Camerini, T.; Carbone, A.; Clemente, C.; Lenisa, L.; Mascheroni, L.; Maurichi, A.; Pennacchioli, E.; et al. Sentinel and nonsentinel node status in stage ib and ii melanoma patients: Two-step prognostic indicators of survival. *J. Clin. Oncol*. 2006, 24, 4464–4471. [CrossRef]
11. Leong, S.P.; Tseng, W.W. Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implications. *CA Cancer J. Clin.* 2014, 64, 195–206. [CrossRef]
12. Salvianti, F.; Massi, D.; De Giorgi, V.; Gori, A.; Pazzagli, M.; Pinzani, P. Evaluation of the liquid biopsy for the detection of brafv600e mutation in metastatic melanoma patients. *Cancer Biomark*. 2019, 26, 271–279. [CrossRef] [PubMed]
13. Huang, S.K.; Hoon, D.S. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. *Mol. Oncol.* 2016, 10, 450–463. [CrossRef] [PubMed]
14. Loeian, M.S.; Mehdi Aghaei, S.; Farhadi, F.; Rai, V.; Yang, H.W.; Johnson, M.D.; Aqil, F.; Mandadi, M.; Rai, S.N.; Panchapakesan, B. Liquid biopsy using the nanotube-ctc-chip: Capture of invasive ctcs with high purity using preferential adherence in breast cancer patients. *Lab Chip* 2019, 19, 1899–1915. [CrossRef] [PubMed]
15. Khosravi, F.; Trainor, P.J.; Lambert, C.; Kloecker, G.; Wickstrom, E.; Rai, S.N.; Panchapakesan, B. Static micro array isolation, dynamic time series classification, capture and enumeration of spiked breast cancer cells in blood: The nanotube-ctc chip. *Nanotechnology* 2016, 27, 44lt03. [CrossRef]
16. Hoshimoto, S.; Shingai, T.; Morton, D.L.; Kuo, C.; Faries, M.B.; Chong, K.; Elashoff, D.; Wang, H.J.; Elashoff, R.M.; Hoon, D.S. Association between circulating tumor cells and prognosis in patients with stage iii melanoma with sentinel lymph node metabolism in a phase iii international multicenter trial. *J. Clin. Oncol.* 2012, 30, 3819–3826. [CrossRef]
17. Nakagawa, T.; Martinez, S.R.; Goto, Y.; Koyanagi, K.; Kitago, M.; Shingai, T.; Elashoff, D.A.; Ye, X.; Singer, F.R.; Giuliano, A.E.; et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. *Clin. Cancer Res.* 2007, 13, 4105–4110. [CrossRef]
18. Lee, J.-H.; Jeong, H.; Choi, J.-W.; Oh, H.E.; Kim, Y.-S. Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis. *Medicine* 2018, 97, e12862. [CrossRef]
19. Mariani, G.; Erba, P.; Manca, G.; Villa, G.; Gipponi, M.; Boni, G.; Buffoni, F.; Suriano, S.; Castagnola, F.; Bartolomei, M.; et al. Radioguided sentinel lymph node biopsy in patients with malignant cutaneous melanoma: The nuclear medicine contribution. *J. Surg. Oncol.* 2004, 85, 141–151. [CrossRef]
20. Perissinotti, A.; Rietbergen, D.D.; Vidal-Sicart, S.; Riera, A.A.; Olmos, R.A.V. Melanoma & nuclear medicine: New insights & advances. *Melanoma Manag.* 2018, 5, MMT06.
21. Quartuccio, N.; Siracusana, M.; Pappalardo, M.; Arnone, A.; Arnone, G. Sentinel node identification in melanoma: Current clinical impact, new emerging spect radiotracers and technological advancements. An update of the last decade. *Curr. Radiopharm.* 2019, 13, 32–41. [CrossRef]
22. Pappalardo, M.; Cheng, M.H. Lymphoscintigraphy for the diagnosis of extremity lymphedema: Current controversies regarding protocol, interpretation, and clinical application. *J. Surg. Oncol.* 2020, 121, 37–47. [CrossRef]
23. Pappalardo, M.; Lin, C.; Ho, O.A.; Kuo, C.F.; Lin, C.Y.; Cheng, M.H. Staging and clinical correlations of lymphoscintigraphy for unilateral gynecological cancer-related lymphedema. *J. Surg. Oncol.* 2019, 121, 422–434. [CrossRef]
24. Bluemel, C.; Herrmann, K.; Gianmarile, F.; Nieweg, O.E.; Dubreuil, J.; Testori, A.; Audisio, R.A.; Zorbas, O.; Lassmann, M.; Chakera, A.H.; et al. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1750–1766. [CrossRef]
25. Hoogendam, J.P.; Veldhuis, W.B.; Hobbelling, M.G.; Verheijen, R.H.; van den Bosch, M.A.; Zweemer, R.P. 99mTc SPECT/CT versus planar lymphoscintigraphy for preoperative sentinel lymph node detection in cervical cancer: A systematic review and metaanalysis. *J. Nucl. Med.* 2015, 56, 675–680. [CrossRef]
43. Trinh, B.B.; Chapman, B.C.; Gleisner, A.; Kwak, J.J.; Morgan, R.; McCarter, M.D.; Gajdos, C.; Kounalakis, N. Spect/ct adds distinct lymph node basins and influences radiologic findings and surgical approach for sentinel lymph node biopsy in head and neck melanoma. *Ann. Surg. Oncol.* 2018, 25, 1716–1722. [CrossRef] [PubMed]

44. van der Ploeg, I.M.; Valdes Olmos, R.A.; Kroon, B.B.; Wouters, M.W.; van den Brekel, M.W.; Vogel, W.V.; Hoefnagel, C.A.; Nieweg, O.E. The yield of spect/ct for anatomical lymphatic mapping in patients with melanoma. *Ann. Surg. Oncol.* 2009, 16, 1537–1542. [CrossRef] [PubMed]

45. Veenstra, H.J.; Vermeerden, L.; Olmos, R.A.; Nieweg, O.E. The additional value of lymphatic mapping with routine spect/ct in unselected patients with clinically localized melanoma. *Ann. Surg. Oncol.* 2012, 19, 1018–1023. [CrossRef]

46. Vermeerden, L.; Valdes Olmos, R.A.; Klop, W.M.; van der Ploeg, I.M.; Nieweg, O.E.; Balm, A.J.; van den Brekel, M.W. Spect/ct for sentinel lymph node mapping in head and neck melanoma. *Head Neck* 2011, 33, 1–6. [CrossRef]

47. Zender, C.; Guo, T.; Weng, C.; Faulhaber, P.; Rezaee, R. Utility of spect/ct for periparotid sentinel lymph node mapping in the surgical management of head and neck melanoma. *Am. J. Otolaryngol.* 2014, 35, 12–18. [CrossRef]

48. Manca, G.; Rubello, D.; Romanini, A.; Boni, G.; Chiaccio, S.; Tredici, M.; Mazzarri, S.; Duc, V.; Colletti, P.M.; Volterrani, D.; et al. Sentinel lymph node mapping in melanoma: The issue of false-negative findings. *Clin. Nucl. Med.* 2014, 39, e346–e354. [CrossRef]

49. Stoffels, I.; Boy, C.; Poppel, T.; Kuhn, J.; Klotgen, K.; Dissemond, J.; Schadendorf, D.; Klode, J. Association between sentinel lymph node excision with or without preoperative spect/ct and metastatic node detection and disease-free survival in melanoma. *JAMA* 2012, 308, 1007–1014. [CrossRef]

50. Manca, G.; Mazzarri, S.; Rubello, D.; Tardelli, E.; Delgado-Bolton, R.C.; Giammarile, F.; Roncella, M.; Volterrani, D.; Colletti, P.M. Radioguided occult lesion localization: Technical procedures and clinical applications. *Clin. Nucl. Med.* 2017, 42, e498–e503. [CrossRef]

51. Hasegawa, B.H.; Wong, K.H.; Iwata, K.; Barber, W.C.; Hwang, A.B.; Sakdinawat, A.E.; Ramaswamy, M.; Price, D.C.; Hawkins, R.A. Dual-modality imaging of cancer with spect/ct. *Technol. Cancer Res. Treat.* 2002, 1, 449–458. [CrossRef]

52. Garau, L.M.; Rubello, D.; Morganti, R.; Boni, G.; Volterrani, D.; Colletti, P.M.; Manca, G. Sentinel lymph node biopsy in small papillary thyroid cancer: A meta-analysis. *Clin. Nucl. Med.* 2019, 44, 107–118. [CrossRef]

53. Tardelli, E.; Mazzarri, S.; Rubello, D.; Gennaro, M.; Fantechi, L.; Duc, V.; Romanini, A.; Chondrogiannis, S.; Volterrani, D.; Colletti, P.M.; et al. Sentinel lymph node biopsy in cutaneous melanoma: Standard and new technical procedures and clinical advances. A systematic review of the literature. *Clin. Nucl. Med.* 2016, 41, e498–e507. [CrossRef]

54. Duc, V.; Manca, G.; Mazzarri, S.; Lorenzetti, F.; Colletti, P.M.; Rubello, D.; Volterrani, D. Sentinel node mapping in melanoma of the back: Spect/ct helps discriminate “true” and “false” in-transit lymph nodes. *Clin. Nucl. Med.* 2016, 41, e66–e67. [CrossRef]

55. Stoffels, I.; Muller, M.; Geisel, M.H.; Leyh, J.; Poppel, T.; Schadendorf, D.; Klode, J. Cost-effectiveness of preoperative spect/ct combined with lymphoscintigraphy vs. Lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. *Eur. J. Nucl. Med. Mol. Imaging* 2014, 41, 1723–1731. [CrossRef]

56. Valdes Olmos, R.A.; Vidal-Sicart, S.; Manca, G.; Mariani, G.; Leon-Ramirez, L.F.; Rubello, D.; Giammarile, F. Advances in radioguided surgery in oncology. *Q. J. Nucl. Med. Mol. Imaging* 2017, 61, 247–270.